Uğurcan Doğan, MD

Nuclear Medicine Resident (3rd year)
Department of Nuclear Medicine, Aydın Adnan Menderes University Faculty of Medicine, Aydın, Türkiye

EMAIL ugurcandogan@adu.edu.tr
EMAIL ugurcandogan1993@gmail.com
WEB nuclearmedicineexplained.com

Nuclear medicine resident with more than 5,000 reported PET/CT studies and a particular interest in FAP-targeted and alpha-emitter theranostics, pretargeted radionuclide therapy and dosimetry. Founder and developer of Nuclear Medicine Explained, a free, open-access learning platform, and of browser-based dosimetry and structured reporting tools. Seeking observerships, research collaboration and funded PhD positions.

CLINICAL EXPERIENCE

Jan 2024 – present — **Resident Physician, Nuclear Medicine** · Aydın Adnan Menderes University Hospital, Aydın, Türkiye

- **PET/CT:** more than 5,000 reports with [^{18}F]FDG, [^{68}Ga]Ga-PSMA and [^{68}Ga]Ga-DOTATATE, including FDG myocardial viability; image analysis in syngo.via and LIFEx.
- **Scintigraphy and SPECT/CT:** myocardial perfusion, thyroid, parathyroid and the general departmental workload.

Sep 2020 – Jan 2024 — **General Practitioner** · Soma State Hospital, Manisa, Türkiye

- Emergency department (1 year) and haemodialysis unit (2.5 years); haemodialysis certificate approved by the Turkish Ministry of Health.

EDUCATION

Jan 2024 – Jan 2028 (expected) — **Residency in Nuclear Medicine** · Aydın Adnan Menderes University Faculty of Medicine, Aydın, Türkiye

2014 – 2020 — **Doctor of Medicine (MD)** · Manisa Celal Bayar University Faculty of Medicine, Manisa, Türkiye

RESEARCH

In progress — **Specialty thesis** · Prognostic value of lesion dissemination (Dmax) on baseline [^{18}F]FDG PET/CT in newly diagnosed multiple myeloma. Retrospective cohort; ethics approval obtained; PET analysis in LIFEx; survival analysis.

EDUCATIONAL PLATFORM AND CLINICAL SOFTWARE

2026 – present — **Founder and Developer, Nuclear Medicine Explained** · free, open-access, English and Turkish

- 78 interactive animations built from referenced data (ENSDF, NIST, current guidelines); 1,765 explained board-style questions with mock exams and spaced review; 29 chapters.
- **Browser-based tools:** dose calculators, TARE dosimetry, structured report templates with dictation, DICOM viewer. Under consideration by the EANM Education Council as suggested reading alongside ESMIT content (Nov 2026).

Clinical tools

- **MIRDy:** Y-90 microsphere dosimetry calculator (single- and dual-compartment MIRD and BSA models, dose-limit warnings).
- **Lymphoma PET/CT:** FDG PET/CT structured reporting tool with lesion-level response tracking.
- **Renal scintigraphy:** browser-based structured report generator.

CERTIFICATES AND CONTINUING MEDICAL EDUCATION

Sep 2026 — **ICPO Academy for Theranostics** · Radiomolecular Precision Oncology, Level 1; ICPO and UEMS certificates; stipend recipient · 18 h · 8.5 ECMEC

Completed — **ESMIT RLT Academy** · Basic RLT Course (radioprotection, radiopharmacy, radiobiology, organisation)

Completed — **ESMIT courses** · Bringing Alpha Therapies into Clinical Practice; Pretargeting Approach and Radiobiology; Personalised Medicine in Prostate Cancer; Parathyroid Imaging · 11.5 ECMEC

2025 — **ESMIT EUROLEARN** · Cardiac Amyloidosis Scintigraphy modules; Focus Meeting 6: Breast Cancer Molecular Imaging

2025 – 2026 — **ESMIT webinars** · FAP and Stroma Imaging (2026); Japanese vs. European View on Targeted Radionuclide Therapy (2025)

Ongoing — ESMIT Advanced RLT Course; further ICPO Academy pillars

RESEARCH INTERESTS

FAPI imaging and theranostics · Targeted alpha therapy · Pretargeted radionuclide therapy · Dosimetry · Medical education

LANGUAGES AND SKILLS

Turkish (native) · English (advanced)
Cross-sectional anatomy · clinical web tool development · AI tools (Claude, OpenEvidence)

Certificates available on request